AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer
AstraZeneca and Merck’s PARP inhibitor Lynparza has chalked up another landmark win.
Months after securing a lightning fast approval for the use of the drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
